Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $205.67 Consensus PT from Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been assigned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $205.6667.

Several research analysts have recently issued reports on the company. UBS Group reissued a “neutral” rating and issued a $188.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer owned 7,012 shares in the company, valued at $1,200,454.40. This represents a 39.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the transaction, the director owned 393,332 shares of the company’s stock, valued at $69,938,362.92. The trade was a 16.46% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 123,791 shares of company stock worth $21,991,850. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in shares of Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares in the last quarter. Capital World Investors raised its holdings in Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after acquiring an additional 111,735 shares during the last quarter. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after purchasing an additional 87,576 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $166.31 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $182.99. The firm has a 50-day moving average of $167.60 and a 200 day moving average of $147.00. The company has a market cap of $10.10 billion, a P/E ratio of -27.40, a PEG ratio of 0.89 and a beta of 0.26.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.